Blood
2010; 116. Available at: https://ash.confex.com/ash/2010/webprogram/Paper29716.html (accessed January 2014). 18 Westrop SJ, Lagos D, Boshoff C et al. African ancestry and innate immunity contribute to the incidence of multicentric Castleman’s disease in HIV-1/Kaposi’s sarcoma herpesvirus- coinfected individuals. Future Virology 2012; 7: 729–734. 19 Algada J, Navani N, Taylor M et al. High prevalence of malignancy in HIV infected patients with enlarged mediastinal lymphadenopathy. Thorax 2010; 65: A169–A170. 20 Du MQ, Liu H, Diss TC et al. Kaposi’s sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman’s disease and associated lymphoproliferative disorders. Blood 2001; 97: 2130–2136. 21 Oksenhendler E, Boulanger E, Galicier L et al. High incidence of Kaposi’s sarcoma-associated Alvelestat in vitro herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman’s disease. Blood 2002; 99: 2331–2336. 22 Arce J, Huang C, Levin M et al. Human herpes virus 8 viral load in multicentric Castleman’s disease. Lab Invest 2010; 90: 285A. 23 Menke DM, Chadbum A, Cesarman E et al. Analysis of the human herpesvirus 8 (HHV-8) genome and
HHV-8 vIL-6 expression in archival cases of Castleman disease at low risk for HIV infection. Am J Clin Pathol 2002; 117: 268–275. 24 Bacon CM, Miller RF, Noursadeghi M et al. Pathology of bone marrow in human herpes virus-8 (HHV8)-associated multicentric Castleman disease. Br J Haematol 2004; 127: 585–591. 25 Grandadam M, Dupin N, Calvez V et al. Exacerbations Dorsomorphin mw of clinical symptoms in human immunodeficiency virus type 1-infected patients with multicentric Castleman’s disease are associated with a high increase in Kaposi’s Inositol monophosphatase 1 sarcoma herpesvirus DNA load in peripheral blood mononuclear cells. J Infect Dis 1997; 175: 1198–1201. 26 Chilton DN, Raja F, Lee SM et al. HIV-associated Multicentric Castleman’s disease (MCD) may present in the context of immune reconstitution (IR); highly active antiretroviral therapy (HAART) alone can modify clinical response and is associated with radiological
response and suppression of Kaposi Sarcoma Herpes Virus (KSHV) viraemia. HIV Med 2009; 10(Suppl 1): 49 [Abstract P132]. 27 Fish R, Paul J, Hargreves S et al. Can KSHV viral load be used to differentiate multicentric Castleman’s disease from Kaposi’s sarcoma? HIV Med 2010; 11(Suppl 1): 12 [Abstract O32]. 28 Sayer R, Paul J, Tuke PW et al. Can plasma HHV8 viral load be used to differentiate multicentric Castleman disease from Kaposi sarcoma? Int J STD AIDS 2011; 22: 585–589. 29 Polizzotto MN, Uldrick TS, Wang V et al. Distinct human and viral interleukin-6 profiles and other viral and immunologic abnormalities in KSHV-associated multicentric Castleman disease: Relationship with disease activity and individual disease manifestations. Blood (ASH Annual Meeting Abstracts) 2011; 118: Abstract 1573. 30 Stebbing J, Adams C, Sanitt A et al.